Q-omics provides the consensus-scored LLCFC1 profile across patient tissues and cancer cell-line models. LLCFC1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LLCFC1 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, LLCFC1 RNA expression shows 13,171 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KICH, and THYM as cancer lineages where LLCFC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LLCFC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LLCFC1 survival associations across molecular data types. LLCFC1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LLCFC1 RNA expression–survival associations across cancer types. High LLCFC1 expression shows unfavorable associations in COAD, UCEC, THCA, MESO, KIRC and LIHC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for LLCFC1 RNA expression.
This table summarizes LLCFC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LLCFC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LLCFC1 shows lower tumor expression in KICH, KIRC, THCA and HNSC and higher tumor expression in CHOL and COAD. The KICH box plot shows higher LLCFC1 RNA expression in normal versus tumor tissue (log2 FC = −0.323, t-test p < 0.001).
This table shows molecular features associated with LLCFC1 in patient tissues and cancer cell lines. In patient samples, LLCFC1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LLCFC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_NSCLC_LUAD.
